Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population
Patients with myasthenia gravis (MG) undergoing immunomodulating therapies are at an increased risk of serious infections. However, the risk of developing self-limited infections, particularly upper respiratory tract infections (URTI), remains unclear. This study aimed to determine the frequency of...
Gespeichert in:
| Veröffentlicht in: | Clinical neurology and neurosurgery 2025-01, Vol.248, p.108649, Article 108649 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 108649 |
| container_title | Clinical neurology and neurosurgery |
| container_volume | 248 |
| creator | Alqahtani, Hussain M. Alanazy, Talal M. Namshah, Abdulmajeed S. Alshuaibi, Faisal T. Albulaihe, Hana Alhammad, Reem M. Alanazy, Mohammed H. |
| description | Patients with myasthenia gravis (MG) undergoing immunomodulating therapies are at an increased risk of serious infections. However, the risk of developing self-limited infections, particularly upper respiratory tract infections (URTI), remains unclear. This study aimed to determine the frequency of URTI among patients with MG compared to the general population and to identify potential predisposing factors.
A monthly questionnaire was administered to patients with MG and a control group over a period of 6 months. The questionnaire assessed the presence of URTI symptoms within the previous month. Statistical analysis was conducted using a chi-square or Fischer exact test, as appropriate.
The study included 161 participants (50 MG patients and 111 control subjects). The frequency of URTI was comparable between the MG group (70 %) and controls (82 %) (p = 0.09). Among patients with MG, a higher proportion of patients who received rituximab developed URTI (93 %) than those who did not (61 %), P = 0.04.
The frequency of URTI was similar in patients with MG compared to the general population. Due to the small sample size and several other limitations, further research is warranted to validate these findings and explore associations between rituximab and URTI.
•The frequency of URTIs is similar between patients with MG and the general population.•Rituximab use increases susceptibility to URTIs in patients with MG. |
| doi_str_mv | 10.1016/j.clineuro.2024.108649 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3140888164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303846724005365</els_id><sourcerecordid>3140888164</sourcerecordid><originalsourceid>FETCH-LOGICAL-c273t-f0a4c4d766c8f5074cee172219276877b56dfd28d833128966ffa5ba49608d4b3</originalsourceid><addsrcrecordid>eNqFkU9v3CAQxVGVqNmm_QoRUi-9eMs_A761ipq2UqRe0jNiYUhY2cYFnGq_fVht0kMvOTGC37xh3kPoipItJVR-3m_dGGdYc9oywkS71FIMb9CGasU6OUh9hjaEE95pIdUFelfKnhDCudRv0QUfJO25UBu03mT4s8LsDjgFvC4LZJyhLDHbmvIB12xdxXEO4GpMc2klXmyNMNeC_8b6gKeDLfUB5mjxfbaPsWCXpsVm8Lgm3F7wPcyQ7YiXtKyjPcq8R-fBjgU-PJ-X6PfNt7vrH93tr-8_r7_edo4pXrtArHDCKymdDj1RwgFQxRgdmJJaqV0vffBMe805ZXqQMgTb76wYJNFe7Pgl-nTSXXJqW5ZqplgcjKOdIa3FcCqI1ppK0dCP_6H7tOa5_e5IsV4J1etGyRPlciolQzBLjpPNB0OJOQZj9uYlGHMMxpyCaY1Xz_LrbgL_r-0liQZ8OQHQ_HiMkE1xzWUHPubmvfEpvjbjCU2VpDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3142574758</pqid></control><display><type>article</type><title>Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Alqahtani, Hussain M. ; Alanazy, Talal M. ; Namshah, Abdulmajeed S. ; Alshuaibi, Faisal T. ; Albulaihe, Hana ; Alhammad, Reem M. ; Alanazy, Mohammed H.</creator><creatorcontrib>Alqahtani, Hussain M. ; Alanazy, Talal M. ; Namshah, Abdulmajeed S. ; Alshuaibi, Faisal T. ; Albulaihe, Hana ; Alhammad, Reem M. ; Alanazy, Mohammed H.</creatorcontrib><description>Patients with myasthenia gravis (MG) undergoing immunomodulating therapies are at an increased risk of serious infections. However, the risk of developing self-limited infections, particularly upper respiratory tract infections (URTI), remains unclear. This study aimed to determine the frequency of URTI among patients with MG compared to the general population and to identify potential predisposing factors.
A monthly questionnaire was administered to patients with MG and a control group over a period of 6 months. The questionnaire assessed the presence of URTI symptoms within the previous month. Statistical analysis was conducted using a chi-square or Fischer exact test, as appropriate.
The study included 161 participants (50 MG patients and 111 control subjects). The frequency of URTI was comparable between the MG group (70 %) and controls (82 %) (p = 0.09). Among patients with MG, a higher proportion of patients who received rituximab developed URTI (93 %) than those who did not (61 %), P = 0.04.
The frequency of URTI was similar in patients with MG compared to the general population. Due to the small sample size and several other limitations, further research is warranted to validate these findings and explore associations between rituximab and URTI.
•The frequency of URTIs is similar between patients with MG and the general population.•Rituximab use increases susceptibility to URTIs in patients with MG.</description><identifier>ISSN: 0303-8467</identifier><identifier>ISSN: 1872-6968</identifier><identifier>EISSN: 1872-6968</identifier><identifier>DOI: 10.1016/j.clineuro.2024.108649</identifier><identifier>PMID: 39615347</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; Coronaviruses ; COVID-19 ; Drug dosages ; Female ; Frequency ; Humans ; Immunologic Factors - therapeutic use ; immunomodulating medications ; Infections ; Male ; Middle Aged ; Myasthenia gravis ; Myasthenia Gravis - complications ; Myasthenia Gravis - epidemiology ; Neuromuscular junctions ; Patients ; Population ; Population studies ; Questionnaires ; Respiratory tract infection ; Respiratory Tract Infections - complications ; Respiratory Tract Infections - epidemiology ; Rituximab ; Rituximab - therapeutic use ; Statistical analysis ; Surveys and Questionnaires ; Upper respiratory tract infection, URTI</subject><ispartof>Clinical neurology and neurosurgery, 2025-01, Vol.248, p.108649, Article 108649</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><rights>2024. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c273t-f0a4c4d766c8f5074cee172219276877b56dfd28d833128966ffa5ba49608d4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0303846724005365$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39615347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alqahtani, Hussain M.</creatorcontrib><creatorcontrib>Alanazy, Talal M.</creatorcontrib><creatorcontrib>Namshah, Abdulmajeed S.</creatorcontrib><creatorcontrib>Alshuaibi, Faisal T.</creatorcontrib><creatorcontrib>Albulaihe, Hana</creatorcontrib><creatorcontrib>Alhammad, Reem M.</creatorcontrib><creatorcontrib>Alanazy, Mohammed H.</creatorcontrib><title>Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population</title><title>Clinical neurology and neurosurgery</title><addtitle>Clin Neurol Neurosurg</addtitle><description>Patients with myasthenia gravis (MG) undergoing immunomodulating therapies are at an increased risk of serious infections. However, the risk of developing self-limited infections, particularly upper respiratory tract infections (URTI), remains unclear. This study aimed to determine the frequency of URTI among patients with MG compared to the general population and to identify potential predisposing factors.
A monthly questionnaire was administered to patients with MG and a control group over a period of 6 months. The questionnaire assessed the presence of URTI symptoms within the previous month. Statistical analysis was conducted using a chi-square or Fischer exact test, as appropriate.
The study included 161 participants (50 MG patients and 111 control subjects). The frequency of URTI was comparable between the MG group (70 %) and controls (82 %) (p = 0.09). Among patients with MG, a higher proportion of patients who received rituximab developed URTI (93 %) than those who did not (61 %), P = 0.04.
The frequency of URTI was similar in patients with MG compared to the general population. Due to the small sample size and several other limitations, further research is warranted to validate these findings and explore associations between rituximab and URTI.
•The frequency of URTIs is similar between patients with MG and the general population.•Rituximab use increases susceptibility to URTIs in patients with MG.</description><subject>Adult</subject><subject>Aged</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Frequency</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>immunomodulating medications</subject><subject>Infections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myasthenia gravis</subject><subject>Myasthenia Gravis - complications</subject><subject>Myasthenia Gravis - epidemiology</subject><subject>Neuromuscular junctions</subject><subject>Patients</subject><subject>Population</subject><subject>Population studies</subject><subject>Questionnaires</subject><subject>Respiratory tract infection</subject><subject>Respiratory Tract Infections - complications</subject><subject>Respiratory Tract Infections - epidemiology</subject><subject>Rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>Statistical analysis</subject><subject>Surveys and Questionnaires</subject><subject>Upper respiratory tract infection, URTI</subject><issn>0303-8467</issn><issn>1872-6968</issn><issn>1872-6968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v3CAQxVGVqNmm_QoRUi-9eMs_A761ipq2UqRe0jNiYUhY2cYFnGq_fVht0kMvOTGC37xh3kPoipItJVR-3m_dGGdYc9oywkS71FIMb9CGasU6OUh9hjaEE95pIdUFelfKnhDCudRv0QUfJO25UBu03mT4s8LsDjgFvC4LZJyhLDHbmvIB12xdxXEO4GpMc2klXmyNMNeC_8b6gKeDLfUB5mjxfbaPsWCXpsVm8Lgm3F7wPcyQ7YiXtKyjPcq8R-fBjgU-PJ-X6PfNt7vrH93tr-8_r7_edo4pXrtArHDCKymdDj1RwgFQxRgdmJJaqV0vffBMe805ZXqQMgTb76wYJNFe7Pgl-nTSXXJqW5ZqplgcjKOdIa3FcCqI1ppK0dCP_6H7tOa5_e5IsV4J1etGyRPlciolQzBLjpPNB0OJOQZj9uYlGHMMxpyCaY1Xz_LrbgL_r-0liQZ8OQHQ_HiMkE1xzWUHPubmvfEpvjbjCU2VpDQ</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Alqahtani, Hussain M.</creator><creator>Alanazy, Talal M.</creator><creator>Namshah, Abdulmajeed S.</creator><creator>Alshuaibi, Faisal T.</creator><creator>Albulaihe, Hana</creator><creator>Alhammad, Reem M.</creator><creator>Alanazy, Mohammed H.</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202501</creationdate><title>Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population</title><author>Alqahtani, Hussain M. ; Alanazy, Talal M. ; Namshah, Abdulmajeed S. ; Alshuaibi, Faisal T. ; Albulaihe, Hana ; Alhammad, Reem M. ; Alanazy, Mohammed H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c273t-f0a4c4d766c8f5074cee172219276877b56dfd28d833128966ffa5ba49608d4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Frequency</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>immunomodulating medications</topic><topic>Infections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myasthenia gravis</topic><topic>Myasthenia Gravis - complications</topic><topic>Myasthenia Gravis - epidemiology</topic><topic>Neuromuscular junctions</topic><topic>Patients</topic><topic>Population</topic><topic>Population studies</topic><topic>Questionnaires</topic><topic>Respiratory tract infection</topic><topic>Respiratory Tract Infections - complications</topic><topic>Respiratory Tract Infections - epidemiology</topic><topic>Rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>Statistical analysis</topic><topic>Surveys and Questionnaires</topic><topic>Upper respiratory tract infection, URTI</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alqahtani, Hussain M.</creatorcontrib><creatorcontrib>Alanazy, Talal M.</creatorcontrib><creatorcontrib>Namshah, Abdulmajeed S.</creatorcontrib><creatorcontrib>Alshuaibi, Faisal T.</creatorcontrib><creatorcontrib>Albulaihe, Hana</creatorcontrib><creatorcontrib>Alhammad, Reem M.</creatorcontrib><creatorcontrib>Alanazy, Mohammed H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neurology and neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alqahtani, Hussain M.</au><au>Alanazy, Talal M.</au><au>Namshah, Abdulmajeed S.</au><au>Alshuaibi, Faisal T.</au><au>Albulaihe, Hana</au><au>Alhammad, Reem M.</au><au>Alanazy, Mohammed H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population</atitle><jtitle>Clinical neurology and neurosurgery</jtitle><addtitle>Clin Neurol Neurosurg</addtitle><date>2025-01</date><risdate>2025</risdate><volume>248</volume><spage>108649</spage><pages>108649-</pages><artnum>108649</artnum><issn>0303-8467</issn><issn>1872-6968</issn><eissn>1872-6968</eissn><abstract>Patients with myasthenia gravis (MG) undergoing immunomodulating therapies are at an increased risk of serious infections. However, the risk of developing self-limited infections, particularly upper respiratory tract infections (URTI), remains unclear. This study aimed to determine the frequency of URTI among patients with MG compared to the general population and to identify potential predisposing factors.
A monthly questionnaire was administered to patients with MG and a control group over a period of 6 months. The questionnaire assessed the presence of URTI symptoms within the previous month. Statistical analysis was conducted using a chi-square or Fischer exact test, as appropriate.
The study included 161 participants (50 MG patients and 111 control subjects). The frequency of URTI was comparable between the MG group (70 %) and controls (82 %) (p = 0.09). Among patients with MG, a higher proportion of patients who received rituximab developed URTI (93 %) than those who did not (61 %), P = 0.04.
The frequency of URTI was similar in patients with MG compared to the general population. Due to the small sample size and several other limitations, further research is warranted to validate these findings and explore associations between rituximab and URTI.
•The frequency of URTIs is similar between patients with MG and the general population.•Rituximab use increases susceptibility to URTIs in patients with MG.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39615347</pmid><doi>10.1016/j.clineuro.2024.108649</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0303-8467 |
| ispartof | Clinical neurology and neurosurgery, 2025-01, Vol.248, p.108649, Article 108649 |
| issn | 0303-8467 1872-6968 1872-6968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3140888164 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Coronaviruses COVID-19 Drug dosages Female Frequency Humans Immunologic Factors - therapeutic use immunomodulating medications Infections Male Middle Aged Myasthenia gravis Myasthenia Gravis - complications Myasthenia Gravis - epidemiology Neuromuscular junctions Patients Population Population studies Questionnaires Respiratory tract infection Respiratory Tract Infections - complications Respiratory Tract Infections - epidemiology Rituximab Rituximab - therapeutic use Statistical analysis Surveys and Questionnaires Upper respiratory tract infection, URTI |
| title | Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A42%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20of%20upper%20respiratory%20tract%20infections%20in%20patients%20with%20myasthenia%20gravis%20compared%20to%20the%20general%20population&rft.jtitle=Clinical%20neurology%20and%20neurosurgery&rft.au=Alqahtani,%20Hussain%20M.&rft.date=2025-01&rft.volume=248&rft.spage=108649&rft.pages=108649-&rft.artnum=108649&rft.issn=0303-8467&rft.eissn=1872-6968&rft_id=info:doi/10.1016/j.clineuro.2024.108649&rft_dat=%3Cproquest_cross%3E3140888164%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3142574758&rft_id=info:pmid/39615347&rft_els_id=S0303846724005365&rfr_iscdi=true |